Craft

Genocea Biosciences

Stock Price

$0

2023-02-23

Market Capitalization

$5.7 K

2023-02-23

Revenue

$1.6 M

FY, 2021

Genocea Biosciences Summary

Company Summary

Overview
Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company is using its proprietary ATLAS antigen identification platform to build a pipeline of immunotherapies that currently includes its lead candidate, GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine.
Type
Public
Status
Active
Founded
2006
HQ
Cambridge, MA, US | view all locations
Website
https://www.genocea.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Chip Clark

    Chip Clark, President, Chief Executive Officer & Director

  • Diantha Duvall

    Diantha Duvall, Chief Financial Officer

  • Jessica Baker Flechtner

    Jessica Baker Flechtner, Chief Scientific Officer

  • Jacquelyn Sumer

    Jacquelyn Sumer, Chief Legal & Compliance Officer

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    100 Acorn Park Dr

Genocea Biosciences Financials

Summary Financials

Revenue (Q1, 2022)
$270.0K
Net income (Q1, 2022)
($16.0M)
Cash (Q1, 2022)
$20.1M

Footer menu